Expert Updates on the Latest Advances in the Development of Weekly Insulin Formulations

CE Information

1.5 CE credits

Completion Time

1 hour, 30 minutes

Available Until

December 31, 2024

Posted By

PCE

Ready to start this activity?

Navigate

Overview

Specialties

Adult, Family, Pediatric, and Women's Health

Subspecialties

Endocrinology

Clinical Topics

Diabetes

Experts provide updates on the development of weekly insulin formulations, including mechanisms of action, efficacy, and safety, as well as strategies to address anticipated patient and healthcare professional barriers to use in clinical practice.

Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits
Nurses: 1.50 Nursing contact hours
Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Released: August 01, 2023
Expiration: December 31, 2024

Learning Objectives

Upon completion of this activity, participants should be able to:

Identify challenges with daily basal insulin that may be overcome by weekly insulin formulations in development
Compare the mechanism of action, efficacy, and safety of weekly insulin formulations in development with available daily basal insulins
Evaluate strategies to address patient and provider barriers to implementing weekly insulins into clinical practice

Speakers

Juan Pablo Frias MD, FACE

Medical Director and Principal Investigator
National Research Institute
Los Angeles, California

Rodolfo J. Galindo MD, FACE

Associate Professor of Medicine
Division of Endocrinology
University of Miami Miller School of Medicine
Director
Comprehensive Diabetes Center
UM Health System
Miami, Florida

Carol Hatch Wysham MD

Clinical Professor of Medicine
Clinical Endocrinologist
MultiCare/Rockwood Clinic
Spokane, Washington

CE Information

This activity offers 1.5 CE credits to attendees.

Accredited by AAPA, ANCC.

The goal of this program is to improve the knowledge and competence of healthcare professionals with the latest evidence on the mechanisms, efficacy, and safety of weekly insulin formulations in development and the potential for these treatments to address challenges with current insulin therapy and achievement of glycemic goals in patients with diabetes.

Jointly provided by Clinical Care Options, LLC and Endocrine Society.

Disclosures

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Rodolfo J. Galindo, MD, FACE

Associate Professor of Medicine
Division of Endocrinology
University of Miami Miller School of Medicine
Director
Comprehensive Diabetes Center
UM Health System
Miami, Florida

Rodolfo J. Galindo, MD, FACE: researcher (paid to institution): Dexcom, Lilly, Novo Nordisk; consultant/advisor/speaker: Bayer, Boehringer Ingelheim, Lilly, Novo Nordisk, Pfizer, Sanofi.

Primary Author

Juan Pablo Frias, MD, FACE

Medical Director and Principal Investigator
National Research Institute
Los Angeles, California

Juan Pablo Frias, MD: researcher (paid to institution): 89bio, Akero, Boehringer Ingelheim, Bristol-Myers Squibb, Intercept, IONIS, Janssen, Lilly, Madrigal, Merck, NorthSea Therapeutics, Novartis, Novo Nordisk, Oramed, Pfizer, Poxel, Sanofi; consultant/advisor/speaker: 89bio, Akero, Altimmune, Axcella Health, Becton Dickenson, Boehringer Ingelheim, Carmot Therapeutics, Echosens, Gilead, Intercept, Lilly, Merck, Metacrine, Novo Nordisk, Pfizer, Sanofi.

Carol Hatch Wysham, MD

Clinical Professor of Medicine
Clinical Endocrinologist
MultiCare/Rockwood Clinic
Spokane, Washington

Carol Hatch Wysham, MD: researcher (paid to institution): Corcept, Lilly, Novo Nordisk, Regeneron, Vanda.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Amy Butts, PA-C as noted below:

Amy Butts, PA-C: consultant/advisor/speaker: Abbott, Bayer, Novo Nordisk, Sanofi.

Ready to start this activity?

Login required. You will be redirected to an external website to register for and complete this activity.

Back to navigate